Germany · Delayed Price · Currency is EUR BioPharma Credit Statistics
Total Valuation
FRA:B3P has a market cap or net worth of EUR 874.23 million. The enterprise value is 870.52 million.
| Market Cap | 874.23M |
| Enterprise Value | 870.52M |
Important Dates
The next estimated earnings date is Wednesday, March 25, 2026.
| Earnings Date | Mar 25, 2026 |
| Ex-Dividend Date | Sep 25, 2025 |
Share Statistics
| Current Share Class | 1.13B |
| Shares Outstanding | n/a |
| Shares Change (YoY) | -7.85% |
| Shares Change (QoQ) | -4.05% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 88.46% |
| Float | 1.06B |
Valuation Ratios
The trailing PE ratio is 8.34.
| PE Ratio | 8.34 |
| Forward PE | n/a |
| PS Ratio | 6.64 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.89 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 10.47 |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 8.30 |
| EV / Sales | 6.54 |
| EV / EBITDA | n/a |
| EV / EBIT | 8.22 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.87
| Current Ratio | 7.87 |
| Quick Ratio | 7.87 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 10.35% and return on invested capital (ROIC) is 6.47%.
| Return on Equity (ROE) | 10.35% |
| Return on Assets (ROA) | 6.44% |
| Return on Invested Capital (ROIC) | 6.47% |
| Return on Capital Employed (ROCE) | 10.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.13 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.32% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -4.32% |
| 50-Day Moving Average | 0.78 |
| 200-Day Moving Average | 0.77 |
| Relative Strength Index (RSI) | 49.96 |
| Average Volume (20 Days) | 460 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:B3P had revenue of EUR 131.70 million and earned 104.84 million in profits. Earnings per share was 0.09.
| Revenue | 131.70M |
| Gross Profit | 131.70M |
| Operating Income | 104.82M |
| Pretax Income | 104.84M |
| Net Income | 104.84M |
| EBITDA | n/a |
| EBIT | 104.82M |
| Earnings Per Share (EPS) | 0.09 |
Balance Sheet
The company has 3.67 million in cash and n/a in debt, giving a net cash position of 3.67 million.
| Cash & Cash Equivalents | 3.67M |
| Total Debt | n/a |
| Net Cash | 3.67M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 979.49M |
| Book Value Per Share | 0.87 |
| Working Capital | 43.84M |
Cash Flow
| Operating Cash Flow | 83.47M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 100.00%, with operating and profit margins of 79.59% and 79.61%.
| Gross Margin | 100.00% |
| Operating Margin | 79.59% |
| Pretax Margin | 79.61% |
| Profit Margin | 79.61% |
| EBITDA Margin | n/a |
| EBIT Margin | 79.59% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 0.09, which amounts to a dividend yield of 11.18%.
| Dividend Per Share | 0.09 |
| Dividend Yield | 11.18% |
| Dividend Growth (YoY) | -32.68% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 46.01% |
| Buyback Yield | 7.85% |
| Shareholder Yield | 19.02% |
| Earnings Yield | 11.99% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
FRA:B3P has an Altman Z-Score of 83.68 and a Piotroski F-Score of 5.
| Altman Z-Score | 83.68 |
| Piotroski F-Score | 5 |